Glyzia Met 50/1000mg Tablet

Glyzia Met 50/1000mg Tablet is a combination medication containing two active ingredients: Sitagliptin & Metformin. Sitagliptin belongs to the class of drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors, while Metformin is a biguanide antidiabetic agent. This combination tablet is used for the management of type 2 diabetes mellitus.

Uses: Glyzia Met 50/1000mg Tablet is prescribed for the treatment of type 2 diabetes mellitus. It works by:

• Sitagliptin: Increasing the levels of incretin hormones in the body, which help regulate blood sugar levels by stimulating insulin release and decreasing sugar production by the liver.
• Metformin: Improving insulin sensitivity, decreasing sugar production by the liver, and reducing the absorption of glucose from the intestine.

Benefits:

• Blood sugar control: Glyzia Met 50/1000mg Tablet helps lower blood sugar levels by multiple mechanisms, including increasing insulin release, decreasing sugar production by the liver, and improving insulin sensitivity.
• Weight neutrality: Unlike some antidiabetic medications, the combination of Sitagliptin and Metformin is generally weight neutral, meaning it does not typically cause weight gain.
• Cardiovascular benefits: Metformin has been shown to have cardiovascular benefits and is commonly used in patients with type 2 diabetes to reduce the risk of cardiovascular events.

Dosage and Administration: The dosage of Glyzia Met 50/1000mg Tablet is individualized based on factors such as the patient’s blood sugar levels, kidney function, and other medications being taken. It is usually taken once or twice daily, with meals, to reduce gastrointestinal side effects associated with Metformin. The tablet should be swallowed whole with a glass of water.

Precautions:

• Hypoglycemia: Glyzia Met 50/1000mg Tablet may rarely cause hypoglycemia (low blood sugar), particularly when used in combination with other antidiabetic medications. Patients should be educated on the signs and symptoms of hypoglycemia and instructed on appropriate management.
• Renal impairment: Dosage adjustments may be necessary in patients with impaired kidney function to prevent the accumulation of Metformin and its metabolites.
• Lactic acidosis: Metformin can rarely cause a serious side effect called lactic acidosis, particularly in patients with kidney impairment or other risk factors. Patients should be monitored for signs and symptoms of lactic acidosis, such as muscle pain, weakness, and respiratory distress.

In Summary: Glyzia Met 50/1000mg Tablet combines Sitagliptin and Metformin, two antidiabetic medications, for the treatment of type 2 diabetes mellitus. By increasing insulin release, decreasing sugar production by the liver, and improving insulin sensitivity, this combination tablet helps control blood sugar levels and improve glycemic control in patients with diabetes.